Results 201 to 210 of about 321,890 (254)

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression - the PRIME-PRAXOL randomized controlled trial

Ventorp F, Lindahl J, Möller S, Asp M, Olsson S, Svensson M, Ängeby F, Pravdinske A, Tjernberg J, Schrey S, Ståhl D, Magnusson V, Eliasson E, Westen Dv, Deierborg T, Månsson K, Pizzagalli D, Hammar Å, Tornberg Å, Björkstrand J, Lindqvist D.   +20 more
europepmc   +1 more source

Integral Solvent-Induced Protein Precipitation for Target-Engagement Studies in <i>Plasmodium falciparum</i>. [PDF]

ACS Infect Dis
Bravo P, Bizzarri L, Steinbrunn D, Lohse J, Hirsch AKH, Mäser P, Rottmann M, Hahne H.   +7 more
europepmc   +1 more source

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, EarlyView.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Engagement Patterns With an Artificial Intelligence Health Coach for Systemic Sclerosis Self‐Management: A Mixed Methods Study

Arthritis Care &Research, EarlyView.
Objective To evaluate utility of an artificial intelligence (AI) health coach for systemic sclerosis (SSc) self‐management and identify patterns associated with participant engagement. Methods We conducted a mixed methods study in which an AI health coach, powered by a large language model (LLM), was used to support self‐management for SSc.
Nirali Shah, Melanie Morris, Cristina Daraban, Sophia Johnson, Susan L. Murphy   +4 more
wiley   +1 more source

Development of Biochemical and Cellular Probes to Study RIPK1 Target Engagement. [PDF]

ACS Med Chem Lett
Yu X, Lin H, Li F, Wang J, Lu D.
europepmc   +1 more source

Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants. [PDF]

Clin Transl Sci
Gonen OM, Porter T, Wang B, Xue F, Ma Y, Song L, Sun P, Fan W, Shen Y.   +8 more
europepmc   +1 more source

Model-Informed Selection of the Recommended Phase 2 Dosage for Anti-TIGIT Immunotherapy Leveraging co-Expressed PD-1 Inhibitor Target Engagement. [PDF]

Clin Pharmacol Ther
Kareva I, Hu P, Pierre V, Kitzing T, Victor A, Richter E, Gao W, Venkatakrishnan K, Zutshi A.   +8 more
europepmc   +1 more source